Stephen Harrow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Stephen Harrow has a total of 177 co-authors. Here are the top co-authors by number of shared publications:
- Alexander V. Louie
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Canada
6 shared publications - Corinne Faivre-Finn
University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK
5 shared publications - David Anthony Palma
Department of Radiation Oncology, London Health Sciences Centre, Western University, London, Canada
5 shared publications - George Rodrigues
London Health Sciences Centre, London, Ontario, Canada
5 shared publications - Stewart Gaede
Department of Medical Biophysics University of Western Ontario London Canada
5 shared publications - Suresh Senan
Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1117 Amsterdam, The Netherlands
5 shared publications
Latest Publications
- Open Access
- 28 May 2026
- Published by Elsevier in Clinical Oncology
- Vol. 56, 104203
Clinical Oncologist and NHS Commissioner Perspectives on Reirradiation for Recurrent Cancer
- 28 May 2026
- Published by Elsevier in Clinical Oncology
- Vol. 56, 104203
Open AccessClinical Oncologist and NHS Commissioner Perspectives on Reirradiation for Recurrent Cancer
- Open Access
- 22 August 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 55, 101036
Re-irradiation of recurrent lung tumours: Associations between dose and 2-year survival
- 22 August 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 55, 101036
Open AccessRe-irradiation of recurrent lung tumours: Associations between dose and 2-year survival
- 14 May 2024
- Published by Elsevier in Lung Cancer
- Vol. 192, 107822
Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study
- 14 May 2024
- Published by Elsevier in Lung Cancer
- Vol. 192, 107822
Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S56-S57
Gross tumour volume predicts survival and correlates with pre-treatment serum albumin concentration in patients with stage III non-small cell lung cancer treated with chemo-radiotherapy
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S56-S57
Gross tumour volume predicts survival and correlates with pre-treatment serum albumin concentration in patients with stage III non-small cell lung cancer treated with chemo-radiotherapy
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S58
Real-world outcomes for patients with inoperable stage III non-small cell lung cancer: a prognostic role for albumin?
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S58
Real-world outcomes for patients with inoperable stage III non-small cell lung cancer: a prognostic role for albumin?
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S33-S34
The Scottish Inflammatory Prognostic Score (SIPS) identifies poor responders to first-line chemoimmunotherapy in non-small cell lung cancer
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S33-S34
The Scottish Inflammatory Prognostic Score (SIPS) identifies poor responders to first-line chemoimmunotherapy in non-small cell lung cancer
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S53-S54
Biomarkers of systemic inflammation predict survival in stage III non-small cell lung cancer treated with chemoradiotherapy
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S53-S54
Biomarkers of systemic inflammation predict survival in stage III non-small cell lung cancer treated with chemoradiotherapy
- Open Access
- 1 November 2020
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 25, 61-66
CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
- 1 November 2020
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 25, 61-66
Open AccessCONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
- Open Access
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
Purpose: The oligometastatic paradigm hypothesizes that patients with a limited number of metastases may achieve long-term disease control, or even cure, if all sites of disease can be ablated. However, long-term randomized data testing this paradigm are lacking. Methods: We enrolled patients with a controlled primary malignancy and 1-5 metastatic lesions, with all metastases amenable to stereotactic ablative radiotherapy (SABR). We stratified by the number of metastases (1-3 vs. 4-5) and randomized in a 1:2 ratio between palliative standard of care (SOC) treatments (Arm 1) vs. SOC plus SABR (Arm 2). We employed a randomized phase II screening design with a primary endpoint of overall survival (OS), using an alpha of 0.20 (wherein a p-value <0.20 indicates a positive trial). Secondary endpoints included progression-free survival (PFS), toxicity, and quality of life (QOL). Herein we present long-term outcomes from the trial. Results: Between 2012 and 2016, 99 patients were randomized (33 in Arm 1, 66 in Arm 2) at 10 centres internationally. Median age was 68 (range 43-89) and the majority (n=59; 60%) were male. The most common primary tumor types were breast (n=18), lung (n=18), colorectal (n=18), and prostate (n=16). Median follow-up was 51 months. Five-year OS was 17.7% in Arm 1 (95% confidence interval [CI]: 6-34%) vs. 42.3% in Arm 2 (95% CI: 28-56%; stratified log-rank p=0.006). Five-year PFS was ‘not reached’ in Arm 1 (3.2% [95% CI: 0-14%] at 4-years with last patient censored) and was 17.3% (95% CI: 8-30%) in Arm 2 (p=0.001). There were no new grade 2-5 adverse events and no differences in QOL between arms. Conclusions: With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis, and durable over time. There were no new safety signals, and SABR had no detrimental impact on QOL. ( NCT01446744 ) Funding: Ontario Institute for Cancer Research and London Regional Cancer Program Catalyst Grant
Open AccessStereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
Purpose: The oligometastatic paradigm hypothesizes that patients with a limited number of metastases may achieve long-term disease control, or even cure, if all sites of disease can be ablated. However, long-term randomized data testing this paradigm are lacking. Methods: We enrolled patients with a controlled primary malignancy and 1-5 metastatic lesions, with all metastases amenable to stereotactic ablative radiotherapy (SABR). We stratified by the number of metastases (1-3 vs. 4-5) and randomized in a 1:2 ratio between palliative standard of care (SOC) treatments (Arm 1) vs. SOC plus SABR (Arm 2). We employed a randomized phase II screening design with a primary endpoint of overall survival (OS), using an alpha of 0.20 (wherein a p-value <0.20 indicates a positive trial). Secondary endpoints included progression-free survival (PFS), toxicity, and quality of life (QOL). Herein we present long-term outcomes from the trial. Results: Between 2012 and 2016, 99 patients were randomized (33 in Arm 1, 66 in Arm 2) at 10 centres internationally. Median age was 68 (range 43-89) and the majority (n=59; 60%) were male. The most common primary tumor types were breast (n=18), lung (n=18), colorectal (n=18), and prostate (n=16). Median follow-up was 51 months. Five-year OS was 17.7% in Arm 1 (95% confidence interval [CI]: 6-34%) vs. 42.3% in Arm 2 (95% CI: 28-56%; stratified log-rank p=0.006). Five-year PFS was ‘not reached’ in Arm 1 (3.2% [95% CI: 0-14%] at 4-years with last patient censored) and was 17.3% (95% CI: 8-30%) in Arm 2 (p=0.001). There were no new grade 2-5 adverse events and no differences in QOL between arms. Conclusions: With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis, and durable over time. There were no new safety signals, and SABR had no detrimental impact on QOL. ( NCT01446744 ) Funding: Ontario Institute for Cancer Research and London Regional Cancer Program Catalyst Grant
- Open Access
- 11 December 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-17
Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial
Background: Stereotactic ablative radiotherapy (SABR) has become an established treatment option for medically-inoperable early-stage (Stage I-IIA) non-small cell lung cancer (ES-NSCLC). SABR is able to obtain high rates of local control with low rates of symptomatic toxicity in this patient population. However, in a subset of patients with fibrotic interstitial lung disease (ILD), elevated rates of SABR-related toxicity and mortality have been described. The Assessment of Precision Irradiation in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease (ASPIRE-ILD) study will conduct a thorough prospective evaluation of the clinical outcomes, toxicity, changes in diagnostic test parameters and patient-related outcomes following SABR for ES-NSCLC for patients with fibrotic ILD. Methods: ASPIRE-ILD is a single-arm Phase II prospective study. The accrual target is 39 adult patients with T1–2N0M0 non-small cell lung cancer with co-existing ILD who are not candidates for surgical excision. Pathological confirmation of diagnosis is strongly recommended but not strictly required. Enrolled patients will be stratified by ILD-related mortality risk. The starting SABR dose will be 50 Gy in 5 fractions every other day (biologically effective dose: 100 Gy10 or 217 Gy3), but the radiation dose can be de-escalated up to two times to 50 Gy in 10 fractions daily (75 Gy10 or 133 Gy3) and 45 Gy in 15 fractions daily (58 Gy10 or 90 Gy3). Dose de-escalation will occur if 2 or more of the first 7 patients in a cohort experiences grade 5 toxicity within 6 months of treatment. Similarly, dose de-escalation can also occur if 2 or more of the first 7 patients with a specific subtype of ILD experiences grade 5 toxicity within 6 months of treatment. The primary endpoint is overall survival. Secondary endpoints include toxicity (CTC-AE 4.0), progression-free survival, local control, patient-reported outcomes (cough severity and quality of life), rates of ILD exacerbation and changes in pulmonary function tests/high-resolution computed tomography findings post-SABR. Discussion: ASPIRE-ILD will be the first prospective study specifically designed to comprehensively evaluate the effectiveness and safety of SABR for ES-NSCLC in patients with co-existing ILD. Trial registration: Clinicaltrials.gov identifier: NCT03485378. Date of registration: April 2, 2018.
- 11 December 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-17
Open AccessAssessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial
Background: Stereotactic ablative radiotherapy (SABR) has become an established treatment option for medically-inoperable early-stage (Stage I-IIA) non-small cell lung cancer (ES-NSCLC). SABR is able to obtain high rates of local control with low rates of symptomatic toxicity in this patient population. However, in a subset of patients with fibrotic interstitial lung disease (ILD), elevated rates of SABR-related toxicity and mortality have been described. The Assessment of Precision Irradiation in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease (ASPIRE-ILD) study will conduct a thorough prospective evaluation of the clinical outcomes, toxicity, changes in diagnostic test parameters and patient-related outcomes following SABR for ES-NSCLC for patients with fibrotic ILD. Methods: ASPIRE-ILD is a single-arm Phase II prospective study. The accrual target is 39 adult patients with T1–2N0M0 non-small cell lung cancer with co-existing ILD who are not candidates for surgical excision. Pathological confirmation of diagnosis is strongly recommended but not strictly required. Enrolled patients will be stratified by ILD-related mortality risk. The starting SABR dose will be 50 Gy in 5 fractions every other day (biologically effective dose: 100 Gy10 or 217 Gy3), but the radiation dose can be de-escalated up to two times to 50 Gy in 10 fractions daily (75 Gy10 or 133 Gy3) and 45 Gy in 15 fractions daily (58 Gy10 or 90 Gy3). Dose de-escalation will occur if 2 or more of the first 7 patients in a cohort experiences grade 5 toxicity within 6 months of treatment. Similarly, dose de-escalation can also occur if 2 or more of the first 7 patients with a specific subtype of ILD experiences grade 5 toxicity within 6 months of treatment. The primary endpoint is overall survival. Secondary endpoints include toxicity (CTC-AE 4.0), progression-free survival, local control, patient-reported outcomes (cough severity and quality of life), rates of ILD exacerbation and changes in pulmonary function tests/high-resolution computed tomography findings post-SABR. Discussion: ASPIRE-ILD will be the first prospective study specifically designed to comprehensively evaluate the effectiveness and safety of SABR for ES-NSCLC in patients with co-existing ILD. Trial registration: Clinicaltrials.gov identifier: NCT03485378. Date of registration: April 2, 2018.